Imatinib Mesylate API is a pharmaceutical-grade BCR-ABL tyrosine kinase inhibitor used in the treatment of Chronic Myeloid Leukemia (CML), Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL), Gastrointestinal Stromal Tumors (GIST), Myelodysplastic/Myeloproliferative Diseases (MDS/MPD), Dermatofibrosarcoma Protuberans (DFSP), and other malignancies associated with abnormal tyrosine kinase activity.
Imatinib Mesylate selectively inhibits BCR-ABL, c-KIT, and PDGFR tyrosine kinases, preventing cancer cell proliferation and promoting apoptosis while minimizing damage to normal cells. It is extensively formulated into oral tablet and capsule formulations for long-term targeted cancer therapy.
Manufactured under WHO-GMP-certified facilities, our Imatinib Mesylate API is produced using advanced manufacturing processes to ensure exceptional purity, stability, and batch-to-batch consistency. Every batch undergoes rigorous quality testing and is supplied with complete regulatory documentation, including Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and Product Specifications.
Imatinib Mesylate API is used in targeted oncology formulations for the treatment of chronic myeloid leukemia, gastrointestinal stromal tumors, Philadelphia chromosome-positive acute lymphoblastic leukemia, and other tyrosine kinase-driven cancers.
Imatinib Mesylate selectively inhibits BCR-ABL, c-KIT, and PDGFR tyrosine kinases, blocking cancer cell growth and inducing apoptosis.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation with every shipment.
Yes. We supply Imatinib Mesylate API in commercial quantities with worldwide export support and customized packaging.
Get Bulk Quote via WhatsApp